louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04048044: EFFECTS OF RejuvaMatrix ™ ON TELOMERES
Official title: THE EFFECTS OF THE RejuvaMatrix ™ ON TELOMERES
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Telomeres
Lead sponsor: Holos Institutes of Health, Inc
Sponsor class: OTHER
First posted: 2019-08-07
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Lying for 30 to 60 minutes daily in a field of 75 decibels of electromagnetic energy at 54 to 78 GHz will allow telomeres of white blood cells to regenerate

Detailed description: Individuals who are post menopausal and who do not have an implanted electronic device, such as a pacemaker will have base line white blood cell telomeeres measured at Repeat Diagnostics in Vancouver. They will be supplied with a two inch foam mat in the center of which is copper screen with one pound of crushed sapphire. The mat looks like a mattreess and is placed on top of the regular mattress. Participants are provided with a Tesla coil to be attached to a copper wire coming from the copper screen. They will also be provided with a timer so that they can set the Tesla coil to be activated for a maximum of 60 minutes while they sleep.

Telomeres will be measured at the end of each year for 5 years.

Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

* Implanted electronic device
* Major, debilitating disease
* Person living with an individual who has an implanted device
* Person who is or could become pregnant

Primary outcomes:
measure: Length of telomeres after 5 years compared with baseline
timeFrame: 5 years
Secondary outcomes:
measure: Total Symptom Index
timeFrame: 5 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04180644: Skin Tape Transcriptome Methods in Children
Official title: Evaluation of Novel Skin Tape Transcriptome Methods in Children With Atopic Dermatitis and Healthy Controls
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atopic Dermatitis
Lead sponsor: National Jewish Health
Sponsor class: OTHER
First posted: 2019-11-27
Enrollment: 20
Sex: ALL
Minimum age (years): 4
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators will recruit 20 children; 10 patients with moderate to severe AD and 10 healthy control subjects aged 4-12 (pre-puberty) years of age

Brief summary: This pilot study will evaluate new methods for the collection, storage, shipment, and RNA extraction of skin tape specimens from children with atopic dermatitis (AD) that will facilitate the multi-center SunBeam Birth Cohort study. Additionally, this pilot study will test new methods for the generation of whole transcriptome sequencing data from skin tape RNA and whether these data reflect the transcriptional state of the skin in health and disease.


Eligibility criteria: Inclusion Criteria:

1. Able to provide informed consent/assent.
2. Male or female, 4-12 years of age (prepuberty) inclusive at the time of consenting
3. Participant must be either:

   1. Active atopic dermatitis with two areas of non-lesional AD within 5 cm of the measured lesional area within the same region.

      OR
   2. .No personal history or current manifestations of AD, food allergy, asthma, allergic rhinitis, and no positive prick or blood testing for allergen (based on self-report); and no evidence of dry skin or other skin condition

Exclusion Criteria:

1. Unable to provide consent or comply with the protocol
2. Presence of any skin condition that might compromise the stratum corneum barrier in infants and young children (e.g., ichthyosis, psoriasis, extensive seborrheic dermatitis, scabies)
3. History of any skin reaction to tape, or adhesives
4. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
5. Use of any topical product (e.g., emollient, topical corticosteroids, topical immunomodulatory agents, topical antibiotics) on the area(s) to be tested within 24 hours before the study visit.

Primary outcomes:
measure: skin RNA sequence for (lesional (L) and non-lesional (NL)) Skin Tape Strips (STS)
timeFrame: through study completion, single visit with an average of 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: National Jewish Health and University of Colorado Denver
state: Colorado
Study officials:
References:
Clinical trial NCT01082744: Thoracic Paravertebral Block for Postoperative Analgesia After Video-assisted Thoracic Surgery.
Official title: Thoracic Paravertebral Block: a Comparative Study of Ropivacaine With Ropivacaine and Sufentanil for Treating Pain After Video-assisted Thoracic Surgery.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pain, Postoperative
Keywords: Paravertebral Block
Regional Anesthesia
Anesthetics Local
Ropivacaine
Sufentanil
Pain Postoperative
Chronic Pain
Thoracic Surgery Video-Assisted.
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2010-03-09
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The use of paravertebral catheters is a recommended technique to achieve postoperative analgesia after thoracic surgery. To date there is no consensus on which drug regime (local anesthetics with or without opioid) is best. The aim of this prospective clinical trial is to determine wether the use of ropivacaine and sufentanil injected through a thoracic paravertebral catheter results in decreased acute postoperative pain compared with plain ropivacaine in patients after thoracoscopic lung surgery.


Eligibility criteria: Inclusion Criteria:

* Patient scheduled for planned video-assisted thoracic surgery
* Patient that consent to participate
* Planned placement of paravertebral catheter
* Patient having a medical insurance

Exclusion Criteria:

* Patient less than 18 years
* Refusal to participate
* Known pregnancy
* Known allergies to local anesthetics, sufentanil and /or to iodinated contrast material
* Intolerance to sufentanil and/or morphine
* Chronic consumption of opiates
* Preoperative chronic pain syndrome
* Patient having a contraindication to placement of paravertebrtal catheter

Primary outcomes:
measure: morphine consumption during the first 48 hours
timeFrame: 48 hours
Secondary outcomes:
measure: Acute pain
timeFrame: 48 hours
measure: Biological measurements
timeFrame: 48 hours
measure: Patient satisfaction
timeFrame: 48 hours
measure: Chronic pain
timeFrame: 3 and 6 monthes
Other outcomes:
Locations:
city: Bron
country: France
facility: Hospices Civils de Lyon, Hopital Louis Pradel, Department of Anesthesiology
Study officials:
affiliation: Hospices Civils de Lyon, Hopital Louis Pradel
name: Christian BAUER, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bauer C, Pavlakovic I, Mercier C, Maury JM, Koffel C, Roy P, Fellahi JL. Adding sufentanil to ropivacaine in continuous thoracic paravertebral block fails to improve analgesia after video-assisted thoracic surgery: A randomised controlled trial. Eur J Anaesthesiol. 2018 Oct;35(10):766-773. doi: 10.1097/EJA.0000000000000777.
Clinical trial NCT01315444: Gastric Acid Rebound Secretion Measured by Alkaline Tide
Official title: Gradual Cessation of Proton Pump Inhibitor (PPI) Treatment May Prevent Rebound Acid Secretion in Dyspeptic and Reflux Patients, Measured by the Alkaline Tide Method.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Condition Measuring Alkaline Tide and Filling Symptoms' Questionnaire After Abrupt or Gradual Step Down Cessation of PPI
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2011-03-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Gastro esophageal reflux disease and ulcer related or non-ulcer dyspepsia, attacks 20% of the Western population. These millions of patients are treated continuously with PPI for different periods, many for many years. Recently, rebound acid hypersecretion was recognized as a major clinical event after cessation of PPI therapy. Sustained hypergastrinemia due to daily PPI therapy causes increased acid-secretory capacity that appears when the drug is stopped. The transient increase in blood and urinary pH following gastric secretion has been termed the alkaline tide phenomenon. Carbonic acid, formed in the presence of the enzyme carbonic anhydrase, neutralizes intracellular hydroxyl ions produced as a result of luminal acid secretion. The bicarbonate generated is removed from the cell via the baso-lateral chloride bicarbonate exchanger. The investigators have shown in several studies that this phenomenon parallels acid secretion. Thus, stimulation of acid secretion with test meal increased base excess maximally after 45 minutes and these changes parallel peak acid output measured in gastric aspirate. The investigators hypothesize that gradual step down cessation of PPI will prevent this clinical relevant event. By measuring alkaline tide after PPI cessation the investigators may prove this hypothesis.


Eligibility criteria: Inclusion Criteria:

* Dyspepsia and reflux patients older than 18

Exclusion Criteria:

* patients on PPI, patients with severe diseases, younger than 18 y, older than 80 y, un-cooperative, COPD, uncompensated IHD, CRF

Primary outcomes:
measure: prevention of acid rebound phenomenon after stoping PPI
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04213144: Evaluate the Influence of Electromagnetic Field as an Adjunctive Non Surgical Treatment in Implant With Peri-implantitis
Official title: Randomized Double Blind Controlled Prospective Study to Evaluate the Influence of Electromagnetic Field as an Adjunctive Non Surgical Treatment in Implant With Peri-implantitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peri-Implantitis
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2019-12-30
Enrollment: 23
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the aim of the study is to compare between two non-surgical methods of treatment of peri-implantitis by using debridement and placing an healing abutment with electomagnetic field (MED-Magdent Miniaturized Device) in the test group and Sham healing abutment in the control group ( Sham MED).

Detailed description: Dental Implants are common alternative for replacement at the time of tooth loss. The two common methods for treatment implant with inflammation include surgical and global non-surgical treatment.

The non-surgical treatment includes soft tissue debridement with various tools which including manual, ultrasonic rotators, lasers and delayed release devices.

Using an electromagnetic field to induce bony healing in fractures and around implants is being investigated for studies and was found to be effective and safe. The electric field lowers osteoclasts activity, speeds up osteoid construction and stimulates creation blood vessels development. Forty patients who will attend to the department of periodontology at Rambam health care campus, at the School ofpostgraduate Dentistry, which will meet the research criteria, will be recruited. All patients will exhibit a moderate-onset gum infection around one of the implants.

Eligibility criteria: Inclusion Criteria:

* Written informed consent.
* Patients of 20 - 85 years.
* pocket depth of 5-8 mm and bone loss of 3-5mm Patients with fixed prosthodontics Implant with standart width

Exclusion Criteria:

* Heavy smokers (more than 10 cigarettes per day).
* Pregnant women
* active periodontal disease
* Consumption of Non Steroidal Anti Inflammatory drugs

Primary outcomes:
measure: Change in the implant probing depth (IPD)
timeFrame: baseline, 4 weeks, 12 weeks
Secondary outcomes:
measure: changing in the concentration of the RANKL cytokine
timeFrame: baseline, 2 weeks, 4 weeks, 12 weeks
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus, Dept. of Periodontology
Study officials:
affiliation: Rambam Health Care Campus
name: Hadar Zigdon, DMD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05956444: NDT on Fall Risk in Cerebral Palsied Children
Official title: Effect of Neurodevelopmental Treatment on Fall Risk and Balance in Children With Spastic Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebral Palsy, Spastic
Falling
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2023-07-21
Enrollment: 44
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Children with spastic cerebral palsy experience falls due to weakness in balance skills and abnormalities in gait parameters. It is necessary to improve the quality of life of these children by reducing the frequency of falling. Aim of this study was to investigate the effect of Neurodevelopmental Treatment on the risk of falling and balance and to contribute to the literature on this subject. Cases were randomized into study and control groups. At the beginning of the study, the balance skills of all the cases with spastic cerebral palsy were measured with the Pediatric Balance Scale, and the gait parameters and fall risks were measured with the LEGSys Temporospatial Gait Analysis Device. Then, an 8-week, case-specific, neurodevelopmental therapy program with intensive gait and balance training was applied to the study group in a 45-minute single session, 2 days a week. The control group received 8 weeks of conventional physiotherapy. At the end of the treatment process, the evaluations were repeated with the same methods.


Eligibility criteria: Inclusion Criteria:

* Cerebral Palsy diagnosis
* Spastic type
* Gross Motor Function Classification System Level I and II

Exclusion Criteria:

* Tendon release surgery or Botox application in the last 6 months

Primary outcomes:
measure: LEGSys, Temporospatial Gait Analysis Device
timeFrame: Beginning of the study
measure: LEGSys, Temporospatial Gait Analysis Device
timeFrame: 8 weeks
measure: Pediatric Balance Scale (PBS)
timeFrame: Beginning of the study
measure: Pediatric Balance Scale (PBS)
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University
Study officials:
affiliation: Faculty Member
name: Fatih Tekin, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT06459544: Effects of Bobath Approach With Core Stability to Improve Balance in Stroke
Official title: Effects of Bobath Approach With Core Stability to Improve Balance in Stroke
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Balance; Distorted
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-06-14
Enrollment: 38
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Bobath technique with core stability exercises to improve balance in stroke. Randomized clinical trial study design will be followed. Data will be collected from following centers: Naseer Hospital, North Ravi Hospital, Bajwa Hoaspital,Minhaj Physiotherapy Centre, Home visits. Probability Random Sampling is used.


Eligibility criteria: Inclusion Criteria:

* age 30 - 65
* Both Gender
* more than 1 month or less than 6 months since onset of stroke
* GCS SCORE 11 TO 15

Exclusion Criteria:

* consist of GCS less than 10
* any pathological fracture
* diagnosed orthostatic hypotension
* Comorbidities like IHD and Rheumatologic disease.

Primary outcomes:
measure: Balance berg scale
timeFrame: 12 Months
measure: Trunk Impairment Scale
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Naseer Hospital 16 A , AHMAD BLOCK NEW GARDEN TOWN
state: Punjab
Study officials:
References:
Clinical trial NCT01081444: Repetitive Transcranial Stimulation (rTMS) in Post Stroke Dysphagia
Official title: Effect of Pharyngeal Inhibition Induced by Repetitive Transcranial Stimulation in Post Stroke Dysphagia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Dysphagia
Stroke
Keywords: repetitive transcranial stimulation
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
First posted: 2010-03-05
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to assess if rTMS on healthy hemisphere at one hertz could improve patients with post stroke dysphagia.


Eligibility criteria: Inclusion Criteria:

* dysphagia
* first episode of stroke

Exclusion Criteria:

* swallowing disorder before stroke
* previous episode of stroke
* MMS \< 20 no consent

Primary outcomes:
measure: Videofluoroscopy and high resolution manometry
timeFrame: day 0, day 14, day 30, day45
Secondary outcomes:
Other outcomes:
Locations:
city: Rouen
country: France
facility: Physiology, Rouen University Hospital
Study officials:
affiliation: University Hospital, Rouen
name: Eric VERIN, MD-PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00123292: Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
Official title: An Open-label, Ascending-dose, Clinical Trial of Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Arterial Occlusive Diseases
Keywords: arterial occlusion
thromboembolism
Acute Peripheral Arterial Occlusion
Lead sponsor: ThromboGenics
Sponsor class: INDUSTRY
First posted: 2005-07-22
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the trial is to evaluate the safety and efficacy of microplasmin administration in patients with acute peripheral arterial occlusion.

Detailed description: This clinical trial is designed as an open-label, dose-escalating, single-centre trial of weight-adjusted dose regimens of microplasmin administered intra-arterially as an infusion to patients with acute peripheral arterial occlusion. Patients who meet all inclusion criteria and none of the exclusion criteria will be administered study drug for up to 4 hours. Different dose regimens will be evaluated in an ascending-dose fashion; an infusion will be administered for up to 4 hours.

Eligibility criteria: Inclusion Criteria:

* Patients presenting within 14 days of onset of acute thrombotic or embolic arterial occlusion of a lower extremity (native vessel or bypass graft).
* Complete occlusion of infrarenal vessel or bypass graft, as determined by angiography.
* Lower extremity ischemia graded as SVS/ISCS (Society of Vascular Surgery/ International Society for Cardiovascular Surgery) class I or II (a or b).
* Negative urine pregnancy test (pregnancy test only required for females of child-bearing potential not using an accepted method of contraception).

Exclusion Criteria:

* Profound ischemia with permanent motor paresis or sensory loss (or ischemic process deemed irreversible, i.e. class III).
* Occlusion not penetrable by the infusion guide wire.
* Known or suspected allergy to contrast agents or heparin sodium.
* Active bleeding or known hemorrhagic diathesis.
* Stroke in the previous 6 months or transient ischemic attack in the previous 2 months.

Primary outcomes:
measure: Complete clot-lysis (defined as >95% estimated clot volume reduction compared to baseline angiogram)
timeFrame: at 4 hours or less (if study drug administration is terminated prior to 4 hours).
Secondary outcomes:
measure: Proportion of subjects with clot-lysis (complete or partial, defined as any clot volume reduction on angiography)
timeFrame: At 4 hours or less (if study drug administration is terminated prior to 4 hours).
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospital Gasthuisberg
Study officials:
affiliation: KU Leuven
name: Peter Verhamme, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03330392: Evaluation of Efficacy and Safety of AGP on Immune Enhancement
Official title: An 8 Week, Randomized, Double-blind, Placebo-controlled Clinical Trial of AGP on Immune Enhancing Effects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Immune Function
Lead sponsor: Chonbuk National University Hospital
Sponsor class: OTHER
First posted: 2017-11-06
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The researchers investigated the immune enhancing effects of AGP for Korean participants.

Detailed description: The aim of the study is to investigate the effects of AGP on immune enhancement based on 8 week, randomized, double-blind, placebo-controlled clinical trial.

Eligibility criteria: Inclusion Criteria:

* The levels of white blood cells within range 3x10\^3/μL\~8x10\^3/μL
* have had at least two cold in the last 12 months.

Exclusion Criteria:

* subjects with BMI\<18.5 kg/m\^2
* subjects taking medications such as immune related drug or functional foods
* history of disease that could interfere with the test products or impede their absorption
* pregnant or lactating women and heavy smokers.
* being judged by the responsible physician of the local study center as unfit to participate in the study

Primary outcomes:
measure: Natural killer cell activity
timeFrame: 0 week, 8 week
Secondary outcomes:
measure: Interleukin-1β
timeFrame: 0 week, 8 week
measure: Interleukin-6
timeFrame: 0 week, 8 week
measure: Interleukin-12 (IL-12)
timeFrame: 0 week, 8 week
measure: Interferon-γ (IFN-γ)
timeFrame: 0 week, 8 week
measure: Tumor necrosis factor-α (TNF-α)
timeFrame: 0 week, 8 week
measure: Changes of White blood cell (WBC)
timeFrame: 0 week, 8 week
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Clinical Trial Center for Functional Foods Chonbuk National University Hospital
state: Jeollabuk-do
Study officials:
References: